3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma
2
Hematologic Neoplasms
2
Subcutaneous panniculitis-like T-cell lymphoma
1
Sezary Syndrome
1
Recurrence
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Infectious Mononucleosis
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Rituximab
15
Cyclophosphamide
12
fludarabine phosphate
11
ibrutinib
10
Bendamustine Hydrochloride
9
fludarabine
7
Peripheral Blood Stem Cell Transplantation
7
Lenalidomide
6
venetoclax
4
Whole-Body Irradiation
4
Radiotherapy
4
idelalisib
3
duvelisib
3
acalabrutinib
3
Mycophenolic Acid
3
Methotrexate
3
Melphalan
3
In Situ Hybridization, Fluorescence
3
Flow Cytometry
3
Filgrastim
3
Cytarabine
3
Cyclosporine
3
ofatumumab
2
obinutuzumab
2
Thiotepa
2
Tacrolimus
2
Pentetic Acid
2
Etoposide
2
Dexamethasone
2
Dasatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
Brentuximab Vedotin
×
Clear all
NCT02623920
2017-05-19
S-BR
University of Arizona
Phase 2
Withdrawn